Eldec Pharmaceuticals, Inc.

Eldec Pharmaceuticals, Inc. is a for-profit corporate entity registered in SAM.gov, located in Durham, North Carolina, with a current registration valid through August 4, 2026. The company appears to be a biotechnology research organization focused on developing novel peptide-based therapeutics targeting complex medical conditions, with a particular emphasis on developing innovative treatments for diseases involving inflammation, viral infections, and genetic disorders. Through its federal grant awards, Eldec Pharmaceuticals specializes in advanced pharmaceutical research and development, leveraging peptide-based approaches to address challenging medical conditions.

The company has secured multiple federal grant awards from prominent research-focused agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Allergy and Infectious Diseases, and the National Center for Advancing Translational Sciences. These grants support sophisticated research projects targeting specific medical challenges, such as developing novel peptide therapeutics for cystic fibrosis-related diabetes, creating peptide immunomodulators for treating sepsis, designing peptide fusion inhibitors for COVID-19 treatment, and exploring strategies to clear bacteria from cystic fibrosis lungs. A recurring theme in Eldec's research is the development of ELD607, a peptidomimetic compound that inhibits ORAI1, a plasma membrane calcium channel implicated in various inflammatory responses. The company's research focuses on mutation-agnostic therapeutic approaches, with preliminary data demonstrating potential efficacy in reducing glucose levels, inflammation, bacterial infection, and fibrosis across different disease models.